CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
For the first time, 70% of cancer patients in the U.S. survive five years or more after diagnosis, according to the American Cancer Society's 2026 report. Advances in immunotherapy, CAR T-cell therapy, and screening technologies have driven significant improvements, particularly for lung cancer and myeloma. The definition of successful cancer care is evolving beyond survival to focus on quality of life and durable remissions.
The CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. The Cell & Gene Therapy Drug Delivery Devices Market is forecast to climb to USD 26.79 billion by 2032 from USD 3.39 billion in 2025.
The global stem cell therapy market is projected to grow from $18.13 billion in 2025 to $59.70 billion by 2035 at a 12.66% CAGR, driven by chronic disease prevalence and regenerative medicine advances.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
Health systems are learning that successful cell and gene therapy programs require early pharmacy involvement, strong payer partnerships, and flexible infrastructure to navigate complex contracts, workflows, and financial realities.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
Moleculin Biotech announced the Japan Patent Office has issued a notice of allowance for a patent covering proprietary methods for reconstituting liposomal Annamycin, strengthening the company's international intellectual property position.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07590648 |
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07441967 |
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation |
NOT_YET_RECRUITING | PHASE2 |
| NCT07359859 |
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant |
RECRUITING | PHASE2 |
| NCT07346105 |
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies |
TEMPORARILY_NOT_AVAILABLE | |
| NCT07316907 |
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07285668 |
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies |
SUSPENDED | NA |
| NCT07255898 |
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07200583 |
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients |
COMPLETED | |
| NCT07195916 |
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies |
RECRUITING | PHASE1 |
| NCT07186192 |
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy |
RECRUITING | PHASE3 |
